Publication:
Expression feature and prognostic function of a novel immune checkpoint Siglec-15 in human colorectal cancer

Thumbnail Image
Files
Liang-40-571-584-2025.pdf(10.18 MB)
Date
2025
relationships.isAuthorOfPublication
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Liang, Guodong ; Zhou, Linyun ; Fan, Yang ; Ding, Run ; Yang, Junrong ; Xu, Li ; Zhu, Yidan ; Huang, Wen
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia, Departamento de Biologia Celular e Histiologia
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-18-801
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Background. Sialic acid-bound immuno-globulin lectin 15 (Siglec-15) plays an important role in the development of cancer. However, the association between Siglec-15 expression and clinicopathological characteristics of colorectal cancer (CRC) has not been fully investigated. Methods. In this present study, a number of bioinformatics analyses were performed to provide an overview and detailed characteristics of Siglec-15. Quantitative real-time polymerase chain reaction (qPCR), western blotting and immunohistochemistry analyses were conducted to characterize the expression of Siglec-15 in CRC. Kaplan-Meier survival and Cox regression analyses were performed to identify the prognostic parameters of CRC. Results. The results of bioinformatics analyses revealed the expression characteristics and prognostic roles of Siglec-15 in CRC. The data of qCPR, western blotting, and IHC analyses demonstrated that the expression of Siglec-15 in CRC tissues was significantly higher than that in non-cancerous tissues. Moreover, the expression level of Siglec-15 in CRC was significantly associated with lymph node metastasis (p=0.001), TNM stage (p=0.001), and overall survival (p=0.026). COX multi-factor analysis indicated that Siglec-15 expression (p=0.023) and tumor differentiation (p=0.003) were independent prognostic factors for CRC. Conclusions. Collectively, the data suggested that Siglec-15 expression may serve as a novel prognostic factor and Siglec-15 might be identified as an ideal candidate for immunotherapy in CRC treatment.
publication.page.subject
Siglec-15 , Colorectal cancer , Prognosis , Immunotherapy
Citation
Histology and Histopathology Vol. 40, nº04 (2025)
URI
http://hdl.handle.net/10201/151914
item.page.embargo
Collections
Histology and histopathology Vol.40, nº4 (2025)
Ir a Estadísticas